Kevin Biglan

12.2k total citations · 3 hit papers
88 papers, 8.1k citations indexed

About

Kevin Biglan is a scholar working on Neurology, Cellular and Molecular Neuroscience and Molecular Biology. According to data from OpenAlex, Kevin Biglan has authored 88 papers receiving a total of 8.1k indexed citations (citations by other indexed papers that have themselves been cited), including 59 papers in Neurology, 32 papers in Cellular and Molecular Neuroscience and 17 papers in Molecular Biology. Recurrent topics in Kevin Biglan's work include Parkinson's Disease Mechanisms and Treatments (47 papers), Neurological disorders and treatments (31 papers) and Genetic Neurodegenerative Diseases (27 papers). Kevin Biglan is often cited by papers focused on Parkinson's Disease Mechanisms and Treatments (47 papers), Neurological disorders and treatments (31 papers) and Genetic Neurodegenerative Diseases (27 papers). Kevin Biglan collaborates with scholars based in United States, United Kingdom and Canada. Kevin Biglan's co-authors include E. Ray Dorsey, Christopher G. Tarolli, William Zhu, Steven Goldenthal, Robert G. Holloway, Jamie Adams, Nirav Sheth, Alexander J. Aranyosi, Gaurav Sharma and Saloni Sharma and has published in prestigious journals such as SHILAP Revista de lepidopterología, Neurology and The Lancet Neurology.

In The Last Decade

Kevin Biglan

88 papers receiving 8.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Multiple Wearable Sensors in Parkinson and Huntington Disease Individuals: A Pilot Study in Clinic and at Home

2017 2.4k citations Saloni Sharma, Kevin Biglan et al. profile →
Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030

2006 1.8k citations E. Ray Dorsey, Kevin Biglan et al. Neurology profile →
Detection of Huntington's disease decades before diagnosis: the Predict-HD study

2007 605 citations Jane S. Paulsen, Douglas R. Langbehn et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kevin Biglan United States	35	5.5k	2.5k	1.5k	1.2k	1.0k	88	8.1k
Joaquim J. Ferreira Portugal	56	7.5k 1.4×	2.7k 1.1×	1.3k 0.9×	1.2k 1.1×	1.1k 1.1×	403	11.6k
Connie Marras Canada	54	6.9k 1.2×	1.9k 0.8×	1.4k 1.0×	1.7k 1.5×	1.2k 1.2×	237	10.5k
Bernard Ravina United States	38	4.9k 0.9×	2.1k 0.8×	1.6k 1.1×	808 0.7×	903 0.9×	84	7.3k
Mario Zappia Italy	47	4.4k 0.8×	1.8k 0.7×	1.2k 0.8×	1.4k 1.2×	959 0.9×	288	8.0k
James H. Bower United States	54	6.2k 1.1×	2.4k 0.9×	923 0.6×	984 0.9×	881 0.9×	151	9.5k
Karl Kieburtz United States	49	5.9k 1.1×	2.9k 1.2×	2.1k 1.5×	1.4k 1.2×	983 1.0×	150	11.7k
Alberto J. Espay United States	55	7.7k 1.4×	2.4k 1.0×	631 0.4×	2.2k 1.9×	1.4k 1.4×	343	11.2k
Nicolaas I. Bohnen United States	57	5.3k 1.0×	2.3k 0.9×	1.1k 0.8×	2.3k 2.0×	2.2k 2.1×	189	10.4k
John E. Duda United States	38	5.7k 1.0×	1.6k 0.6×	673 0.5×	1.6k 1.4×	1.2k 1.2×	61	8.0k
Susan H. Fox Canada	59	9.3k 1.7×	5.0k 2.0×	1.3k 0.9×	1.4k 1.2×	2.1k 2.0×	251	13.2k

Countries citing papers authored by Kevin Biglan

Since Specialization

Citations

This map shows the geographic impact of Kevin Biglan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kevin Biglan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kevin Biglan more than expected).

Fields of papers citing papers by Kevin Biglan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kevin Biglan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kevin Biglan. The network helps show where Kevin Biglan may publish in the future.

Co-authorship network of co-authors of Kevin Biglan

This figure shows the co-authorship network connecting the top 25 collaborators of Kevin Biglan. A scholar is included among the top collaborators of Kevin Biglan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kevin Biglan. Kevin Biglan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wang, Jian, Andrew McCarthy, Xiangnan Dang, et al.. (2022). Evaluating the Use of Digital Biomarkers to Test Treatment Effects on Cognition and Movement in Patients with Lewy Body Dementia. Journal of Parkinson s Disease. 12(6). 1991–2004. 7 indexed citations

Chandler, Julie, et al.. (2022). Disease Progression and Longitudinal Clinical Outcomes of Lewy Body Dementia in the NACC Database. Neurology and Therapy. 12(1). 177–195. 11 indexed citations

Biglan, Kevin, Leanne Munsie, Kjell Svensson, et al.. (2021). Results of the Presence Study Evaluating Mevidalen for the Treatment of Lewy Body Dementia (LBD) (2028). Neurology. 96(15_supplement). 1 indexed citations

Svensson, Kjell, Claire Brittain, Brian J. Eastwood, et al.. (2021). The Dopamine D1 Receptor Positive Allosteric Modulator Mevidalen (LY3154207) Enhances Wakefulness in the Humanized D1 Mouse and in Sleep-Deprived Healthy Male Volunteers. Journal of Pharmacology and Experimental Therapeutics. 380(3). 143–152. 7 indexed citations

Schneider, Ruth B., Taylor Myers, Marie K. Luff, et al.. (2020). A Virtual Cohort Study of Individuals at Genetic Risk for Parkinson’s Disease: Study Protocol and Design. Journal of Parkinson s Disease. 10(3). 1195–1207. 5 indexed citations

Simuni, Tanya, Robert G. Holloway, David Oakes, Kevin Biglan, & Codrin Lungu. (2018). A Phase 3 study of Isradipine as a disease modifying agent in patients with early Parkinson’s disease (STEADY-PD III): Baseline characteristics and study update (P2.039). Neurology. 90(15_supplement). 5 indexed citations

McGarry, Andrew & Kevin Biglan. (2017). Preclinical motor manifestations of Huntington disease. Handbook of clinical neurology. 144. 93–98. 9 indexed citations

Beglinger, Leigh J., William Adams, Jess G. Fiedorowicz, et al.. (2015). Practice Effects and Stability of Neuropsychological and UHDRS Tests Over Short Retest Intervals in Huntington Disease. Journal of Huntington s Disease. 4(3). 251–260. 4 indexed citations

Arora, Siddharth, Vinayak Venkataraman, Sean Donohue, et al.. (2014). High accuracy discrimination of Parkinson's disease participants from healthy controls using smartphones. 3641–3644. 50 indexed citations

10.

Bull, Michael, Kristin C. Darwin, Vinayak Venkataraman, et al.. (2014). A Pilot Study of Virtual Visits in Huntington Disease. Journal of Huntington s Disease. 3(2). 189–195. 42 indexed citations

11.

Dorsey, E. Ray, Vinayak Venkataraman, Michael Bull, et al.. (2013). Randomized Controlled Clinical Trial of “Virtual House Calls” for Parkinson Disease. JAMA Neurology. 70(5). 565–565. 189 indexed citations

12.

Shprecher, David, Katia Noyes, Kevin Biglan, et al.. (2012). Willingness of Parkinson's Disease Patients to Participate in Research Using Internet-Based Technology. Telemedicine Journal and e-Health. 18(9). 684–687. 15 indexed citations

13.

Abdolahi, Amir, et al.. (2012). Potential reliability and validity of a modified version of the Unified Parkinson's Disease Rating Scale that could be administered remotely. Parkinsonism & Related Disorders. 19(2). 218–221. 111 indexed citations

14.

Biglan, Kevin, E. Ray Dorsey, Christopher A. Ross, et al.. (2012). Plasma 8-hydroxy-2′-deoxyguanosine Levels in Huntington Disease and Healthy Controls Treated with Coenzyme Q10. Journal of Huntington s Disease. 1(1). 65–69. 9 indexed citations

15.

Stout, Julie C., Jane S. Paulsen, Sarah Queller, et al.. (2010). Neurocognitive signs in prodromal Huntington disease.. Neuropsychology. 25(1). 1–14. 284 indexed citations

16.

Dorsey, E. Ray, Lisa M. Deuel, Tiffini Voss, et al.. (2010). Increasing access to specialty care: A pilot, randomized controlled trial of telemedicine for Parkinson's disease. Movement Disorders. 25(11). 1652–1659. 138 indexed citations

17.

Dorsey, E. Ray, Tiffini Voss, David Shprecher, et al.. (2010). A U.S. survey of patients with Parkinson's disease: Satisfaction with medical care and support groups. Movement Disorders. 25(13). 2128–2135. 39 indexed citations

18.

Marsh, Laura, Kevin Biglan, Melissa Gerstenhaber, & James R. Williams. (2008). Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: A pilot open‐label study. Movement Disorders. 24(2). 277–282. 106 indexed citations

19.

Holloway, Robert G. & Kevin Biglan. (2002). A review of pramipexole and its clinical utility in Parkinson’s disease. Expert Opinion on Pharmacotherapy. 3(2). 197–210. 26 indexed citations

20.

Biglan, Kevin & Robert G. Holloway. (2001). Initial treatment of early Parkinson’s disease: A review of recent, randomized controlled trials. Current Neurology and Neuroscience Reports. 1(4). 329–336. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact